Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
69
resultados
Última actualización
29/01/2026 [06:45:00]
Resumen de: WO2026020045A1
Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.
Resumen de: WO2026020037A1
This document provides methods and materials involved in binding a molecule (e.g., an antibody domain, an antigen binding fragment, an antibody, a chimeric antigen receptor (CAR), a cell engager, or an antibody-drug conjugate (ADC)) to a CS1 polypeptide. For example, this document provides binders (e.g., antibody domains, antigen binding fragments, antibodies, CARs, cell engagers, and ADCs) that bind to a CS1 polypeptide and methods and materials for using such binders (or cells expressing such binder such as a cell expressing a CAR) to treat cancer (e.g., multiple myeloma).
Resumen de: WO2026017796A1
The present invention relates to a system and a method for measuring and analyzing minimal residual disease (MRD) in pediatric B-cell precursor acute lymphoblastic leukemia (B-ALL) using multiparameter flow cytometry (MPFC). The invention finds application in clinical diagnostics and hematology-oncology for quantifying MRD in B-ALL patients with high sensitivity and specificity, needed for risk stratification, monitoring treatment response, and informing therapeutic decisions. The system comprises interconnected subsystems including an acquisition subsystem with an MPFC instrument, a control and file generation subsystem, and an analytical subsystem. The analytical subsystem incorporates modules for sequential data reduction, automated data cleaning, automated unsupervised data clustering, and interactive cluster analysis. Key advantages include high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity, without reliance on reference samples or supervised machine learning models, making it applicable in laboratories with different measuring equipment and using different panels of antibodies for identification of leukemic cells.
Resumen de: WO2026020038A1
Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate CDK4/6 signaling. The invention encompasses methods for administering N-desmethyl ruboxistaurin to subjects in need, particularly those with a history of cancer or currently experiencing breast cancer, liposarcoma, lung cancer, glioblastoma, melanoma, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, colorectal cancer, bladder cancer, hepatocellular carcinoma, osteosarcoma, germ cell tumors, advanced solid tumors, lymphoma, leukemia and other hematologic malignancies. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, is effective in modulating CDK4/6 signaling while mitigating toxicity associated with other treatments.
Resumen de: AU2025283528A1
The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancers that overexpress the histone methyltransferase WHSC1, e.g., t(4;14) multiple myeloma, by administering to a subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2. ec e c
Resumen de: AU2024283100A1
Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering therapeutically effective amounts of a GPRC5DxCD3 bispecific antibody on a monthly dosing schedule.
Resumen de: AU2024284994A1
Disclosed in the present invention are a CLL1-CAR-T cell, and a preparation method therefor and the use thereof. The CLL1-CAR-T cell contains a chimeric antigen receptor, wherein the chimeric antigen receptor comprises a single domain antibody, a hinge region, a transmembrane region and an intracellular signaling region, and the single domain antibody has an amino acid sequence of positions 22-150 of SEQ ID No. 1. The CLL1-VHH-1 CAR-T cell of the present invention can secrete T cell specific effector molecule IFN-γ to specifically kill CLL1+ target cells, inhibit the proliferation of tumor cells in mice, prolong the survival time of mice, and can be used for immunotherapy of diseases associated with CLL1 target (such as acute myelogenous leukemia).
Resumen de: AU2024275892A1
The present disclosure is concerned with compounds that restore p53 activity and methods of using the compounds in the treatment of various disorders related to loss of p53 activity such as, for example, cancer (e.g, a sarcoma, a carcinoma, a head-and-neck cancer, hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: AU2024283114A1
Provided are methods for treating CD33-positive hematological malignancies, such as acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), harboring mutations such as FLT3, IDH1, IDH2, NMP1, and/or MLL1 gene mutations, using combination therapy that includes one or both of a radiolabeled CD33-targeting agent and a drug-conjugated CD33-targeting agent, and one or more targeted therapies, such as FLT3, IDH and Menin inhibitors.
Resumen de: AU2024296708A1
Methods for treating peripheral T-cell lymphoma include administering to a subject a combination of Cyclophosphamide, Vincristine, Prednisone, and Pralatrexate, wherein the combination does not include doxorubicin. The treatment may be administered in repeated three-week cycles, optionally including a drug holiday.
Resumen de: US20260021088A1
Provided herein are methods of treating B-cell proliferative disorders (such as Follicular Lymphoma “FL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an immunomodulatory agent (such as lenalidomide) and an anti-CD20 antibody (such as obinutuzumab or rituximab).
Resumen de: US20260021093A1
The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of multiple myeloma in a subject in need thereof. The combinations may, optionally, further comprise an anti-inflammatory agent, such as dexamethasone. Also provided herein are methods for treating multiple myeloma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.
Resumen de: US20260021103A1
Provided herein are compounds that promote targeted degradation of IKZF1, IKZF2, GSPT1, and/or CK1a, proteins whose activities are implicated in the pathology of certain cancers (e.g., acute myeloid leukemia). Also provided are pharmaceutical compositions comprising the compounds. Also provided are methods of treating cancer, and methods of promoting the degradation of IKZF1, IKZF2, GSPT1, and/or CK1a in a subject or biological sample by administering a compound or composition described herein.
Resumen de: US20260023068A1
The present invention refers to a method for treating Notch signaling-dependent disease in the subject with a FBXO42 specific inhibitor. The Notch signaling-dependent disease is selected from leukemia. Also provided is a method for screening a drug treating Notch signaling-dependent disease using FBXO42 as a target.
Resumen de: WO2026017800A1
The present invention relates to a reagent panels for the measurement of minimal residual disease (MRD) associated with pediatric B-cell precursor acute lymphoblastic leukemia (B- ALL) by multiparametric flow cytometry. The reagent panel of the invention comprises a combination of antibodies directed against markers, wherein the combination of antibodies comprises i) antibodies targeting markers CD45, CD20, CD34, CD38, CD10, CD58, CD66c, CD73, CD81, CD123, CD304, CD44, CD86, CD99 and CD371, and ii) antibodies targeting markers CD19 and/or CD22, wherein the antibodies are conjugated with fluorochromes. The invention further relates to the use of said panels for detecting MRD associated with B-ALL and/or for identifying a subject at risk of developing B-ALL relapse. The invention also relates to methods of detecting MRD associated with B-ALL. Key advantages of the invention include achieving high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity.
Resumen de: EP4682889A2
The present invention relates generally to classification of biological samples, and more specifically to cell of original classification. In particular, some embodiments of the invention relate to diffuse large B cell lymphoma cell of origin classification using machine learning models. The machine learning models can be based on decision trees such as a random forest algorithm or a gradient boosted decision tree. Features for the models can be determined through analysis of variant data from plasma or blood samples from a plurality of subjects with the disease.
Resumen de: EP4682142A1
The present invention relates to the field of chemical medicines. Disclosed are a 1H-pyrrole-2-amide derivative and a use thereof. In order to obtain a specific inhibitor for an m6A-modified RNA reader protein YTHDC1 of AML, the present invention provides a 1H-pyrrole-2-amide derivative as shown in formula I, wherein said derivative has high inhibitory activity against YTHDC1. In-vitro experiments prove that said derivative can effectively inhibit the proliferation of acute myeloid leukemia cells, significantly arrest a cell cycle of the acute myeloid leukemia cells in the G0/G1 phase, and induce differentiation and apoptosis of the acute myeloid leukemia cells. A compound and a salt thereof or a pharmaceutical composition of the 1H-pyrrole-2-amide derivative of the present invention provide new options for antitumor drug development targeting YTHDC1 in the art, and have good application prospects.
Resumen de: US20260014252A1
The present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that binds specifically to GPRC5D and a second antigen-binding domain that binds specifically to CD28. In certain embodiments, the antigen-binding molecules are bispecific antibodies or antigen-binding fragments thereof that comprise a first antigen-binding domain that binds specifically to GPRC5D and a second antigen-binding domain that binds specifically to CD28. In certain embodiments, the bispecific antibodies are useful for treating a cancer (e.g., multiple myeloma).
Resumen de: US20260014226A1
The invention is directed to room temperature stable injectable formulations of carfilzomib or its pharmaceutically acceptable derivatives thereof in the form of ready to dilute solution and concentrates with no hemolytic potential. Further the invention is directed to a method for treating patients with relapsed or refractory multiple myeloma by administering such composition.
Resumen de: US20260014129A1
The invention relates to the treatment of chronic myeloid leukemia (CML). In particular it relates to the treatment of CML with inhibitors of mitochondrial pyruvate transport, which are able to target leukemic stem cells (LSCs) which are resistant to therapy with tyrosine kinase inhibitors (TKIs). Combination therapies with BCR-ABL kinase inhibitors are also described.
Resumen de: WO2026015480A1
This invention pertains to fusion protein mutants comprising a Prime Editing enzyme having a first amino acid sequence and a second amino acid sequence, wherein the first amino acid sequence comprises a SpCas9 H840A nickase mutant protein of SEQ ID NO:152 and the second amino acid sequence comprises a Moloney Murine Leukemia Virus reverse transcriptase protein mutant (MMLV RTase mutant), wherein the fusion protein mutant displays at least the equivalent or greater activity of a reference Prime Editing enzyme in genome editing.
Resumen de: WO2026012487A1
Provided is a bispecific CAR-T cell targeting BCMA and GPRC5D. Specifically, provided is an autologous CAR-T cell targeting both BCMA and GPRC5D antigen molecules and expressing chimeric antigen receptors (CARs) in parallel. Also provided is a use of a CAR-T cell for adoptive T-cell therapy for diseases including multiple myeloma.
Resumen de: US20260015421A1
Described are γδ T-cells that express a non-signaling chimeric antigen receptor (CAR), wherein the CAR binds a tumor antigen such as CD19 or CD33. Also described are pharmaceutical compositions thereof and the method for the treatment of cancer such as leukemia.
Resumen de: US20260015406A1
The present invention includes compositions and methods for retrieving tumor-related antibodies and antigens. In one aspect, the invention includes a method for Sequential Tumor-related Antibody and antigen Retrieving (STAR) which directly and efficiently identifies potent antibodies that can specifically bind to tumor-related antigens on the tumor cell surface. In another aspect, the invention includes a CAR comprising a nanobody, a transmembrane domain, and an intracellular domain, wherein the nanobody is retrieved by a STAR method. In another aspect, the invention includes a CAR T system that targets CD13 and treats acute myeloid leukemia. In another aspect, the invention includes a CAR T system and ADC that targets CDH17 and treats NETs and other types of tumors expressing this antigen, with tolerable toxicities.
Nº publicación: US20260014255A1 15/01/2026
Solicitante:
MENDUS B V [NL]
MENDUS B.V
Resumen de: US20260014255A1
The present disclosure provides methods for treating a progressive ovarian cancer using an allogeneic leukemia-derived cell. Also provided are immunogenic compositions comprising an allogeneic leukemia-derived cell, and pharmaceutical compositions and formulations thereof.
BOPI
Sede Electrónica
